Aries Wealth Management Makes New $1.67 Million Investment in IDEXX Laboratories, Inc. $IDXX

Key Points

• Aries Wealth Management acquired 3,199 shares of IDEXX Laboratories worth approximately $1.67 million during the third quarter. Other institutions also increased their positions, and institutional investors collectively own 87.84% of the company.
• Analyst sentiment remains favorable, with seven Buy ratings and five Holds producing a “Moderate Buy” consensus and an average price target of $744.09. Goldman Sachs initiated coverage with a $740 target, while JPMorgan set a $750 target and Overweight rating.
• IDEXX reported quarterly earnings of $4.27 per share, exceeding estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company provided fiscal 2026 EPS guidance of $14.69 to $14.94.

Aries Wealth Management acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,199 shares of the company's stock, valued at approximately $1,670,000.

A number of other large investors have also made changes to their positions in IDXX. Live Oak Investment Partners lifted its stake in shares of IDEXX Laboratories by 1.5% during the third quarter. Live Oak Investment Partners now owns 2,516 shares of the company's stock valued at $1,314,000 after buying an additional 38 shares during the period. Signaturefd LLC lifted its stake in shares of IDEXX Laboratories by 21.4% during the 3rd quarter. Signaturefd LLC now owns 1,964 shares of the company's stock worth $1,026,000 after purchasing an additional 346 shares during the period. Citizens Financial Group Inc. RI lifted its stake in shares of IDEXX Laboratories by 51.1% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 3,400 shares of the company's stock worth $1,776,000 after purchasing an additional 1,150 shares during the period. One Wealth Capital Management LLC acquired a new position in shares of IDEXX Laboratories during the third quarter worth $699,000. Finally, Mascoma Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 41.7% in the third quarter. Mascoma Wealth Management LLC now owns 170 shares of the company's stock valued at $89,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.79% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group initiated coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They set a "buy" rating and a $740.00 price target for the company. Citigroup boosted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. JPMorgan Chase & Co. lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating for the company in a research note on Friday, October 16th. Weiss Ratings raised IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Finally, Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Seven research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $744.09.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $560.38 on Monday. The firm has a 50 day simple moving average of $532.69 and a 200-day simple moving average of $551.46. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock has a market capitalization of $44.15 billion, a PE ratio of 39.41 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The business had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the prior year, the firm posted $3.50 earnings per share. The company's revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.